{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:54:36Z","timestamp":1788454476581,"version":"build-2803163510"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>The presence of leukocytes in the cerebral spinal fluid (CSF) of patients with acute lymphoblastic leukemia may indicate a relapse in the central nervous system. CD19-directed immunotherapy may increase the blood-brain barrier permeability, leading to neurologic toxicity and infiltrate the CNS. We studied the CSF cell and protein content in 71 consecutive patients who received either CD19 chimeric antigen receptor T cells or blinatumomab. Responding patients had an incidence of 66% and 61% of pleocytosis following blinatumomab or chimeric antigen receptor T cells, respectively. CSF parameters did not correlate with toxicity or prior CNS disease. Routine CSF flow cytometry following immunotherapy to distinguish T-cell infiltration from CNS relapse should be considered.<\/jats:p>","DOI":"10.1097\/mph.0000000000002765","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T07:51:01Z","timestamp":1696837861000},"page":"29-32","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Cerebral Spinal Fluid Parameters Following CD19-Targeted Therapies in Children and Young Adults"],"prefix":"10.1097","volume":"46","author":[{"given":"Shiran","family":"Leib","sequence":"first","affiliation":[{"name":"Division of Pediatric Hematology and Oncology, The Edmond and Lily Safra Children\u2019s Hospital, Sheba Medical Center, Tel Hashomer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bella","family":"Bielorai","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology and Oncology, The Edmond and Lily Safra Children\u2019s Hospital, Sheba Medical Center, Tel Hashomer"},{"name":"Faculty of Medicine, Tel Aviv University, Tel Aviv"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helly","family":"Vernitsky","sequence":"additional","affiliation":[{"name":"Hematology Lab, Sheba Medical Center, Tel Hashomer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yarden","family":"Aharony-Tevet","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Tel Aviv University, Tel Aviv"},{"name":"Immunotherapy Lab, Sheba Medical Center, Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amos","family":"Toren","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology and Oncology, The Edmond and Lily Safra Children\u2019s Hospital, Sheba Medical Center, Tel Hashomer"},{"name":"Faculty of Medicine, Tel Aviv University, Tel Aviv"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Jacoby","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology and Oncology, The Edmond and Lily Safra Children\u2019s Hospital, Sheba Medical Center, Tel Hashomer"},{"name":"Faculty of Medicine, Tel Aviv University, Tel Aviv"},{"name":"Immunotherapy Lab, Sheba Medical Center, Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"key":"R1-20250804","first-page":"404","article-title":"The increasing incidence of central nervous system leukemia in children","volume":"26","author":"Evans","year":"1970","journal-title":"Children\u2019s cancer study group a Cancer"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N Engl J Med"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1182\/blood.2019004043","article-title":"How I treat relapsed acute lymphoblastic leukemia in the pediatric population","volume":"136","author":"Hunger","year":"2020","journal-title":"Blood"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1200\/JCO.2005.03.3373","article-title":"Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study","volume":"24","author":"Barredo","year":"2006","journal-title":"J Clin Oncol"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"e108107","DOI":"10.1371\/journal.pone.0108107","article-title":"Outcome of central nervous system relapses in childhood acute lymphoblastic Leukaemia - Prospective open cohort analyses of the ALLR3 trial","volume":"9","author":"Masurekar","year":"2014","journal-title":"PLoS One"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2012-02-265884","article-title":"How I treat relapsed childhood acute lymphoblastic leukemia","volume":"120","author":"Locatelli","year":"2012","journal-title":"Blood"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/Phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"Von Stackelberg","year":"2016","journal-title":"J Clin Oncol"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41408-020-00342-x","article-title":"Blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study","volume":"10","author":"Locatelli","year":"2020","journal-title":"Blood Cancer J"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of b-cell acute lymphoblastic leukemia: A randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA - J Am Med Assoc"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse b-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA - J Am Med Assoc"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-Cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J Clin Oncol"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J Clin Invest"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/bjh.18105","article-title":"Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with B-acute lymphoblastic leukaemia","volume":"197","author":"Jacoby","year":"2022","journal-title":"Br J Haematol"},{"key":"R16-20250804","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J Clin Oncol"},{"key":"R17-20250804","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","article-title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia","volume":"35","author":"Dourthe","year":"2021","journal-title":"Leukemia"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"e003644","DOI":"10.1136\/jitc-2021-003644","article-title":"Factors associated with the clinical outcome of patients with relapsed\/refractory CD19 + acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy","volume":"9","author":"Ortiz-Maldonado","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R19-20250804","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41375-022-01546-9","article-title":"CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study","volume":"36","author":"Jacoby","year":"2022","journal-title":"Leukemia"},{"key":"R20-20250804","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/bloodadvances.2021005564","article-title":"Tisagenlecleucel outcomes in relapsed\/refractory extramedullary ALL: a pediatric real world CAR consortium report","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv"},{"key":"R21-20250804","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"R22-20250804","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ana.25502","article-title":"Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy","volume":"86","author":"Gust","year":"2019","journal-title":"Ann Neurol"},{"key":"R23-20250804","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1182\/blood.2021012328","article-title":"Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium","volume":"139","author":"Buchmann","year":"2022","journal-title":"Blood"},{"key":"R24-20250804","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R25-20250804","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"R26-20250804","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"key":"R27-20250804","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"R28-20250804","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajh.24783","article-title":"Correlates of resistance and relapse during blinatumomab therapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"92","author":"Aldoss","year":"2017","journal-title":"Am J Hematol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002765","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:03:42Z","timestamp":1754337822000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002765","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,9]]},"assertion":[{"value":"2023-04-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}